​​​​News and Events

December 2017

Beacon Biomedical Inc.completed its non-clinical and clinical studies for BeScreened™-CRC and receives its CLIA approval for clinical use as a blood-based colorectal screening test for screening non-compliant patients.  The test is 95% accurate and is now available to the public through partnered ACOs and Independent Physicians Offices.

Press Release

May 2017

​​Beacon Biomedical has  been selected as finalists to present at the 2017 Bio Start-up Stadium Event on June 22nd at Bio International Convention being held in San Diego June 18th-22nd. 

March 2017

March is Colorectal Cancer (CRC) Awareness Month.  Be Aware, Be Prepared & Get Screened for CRC.


February 2017
Beacon Biomedical Inc. receives its CLIA Laboratory ID (Number 03D2122615) from the Centers for Medicare & Medicaid Services, effective as of December 1, 2016

Beacon Biomedical Inc. and Sonora Quest Laboratories (SQL) have executed a Laboratory Draw Agreement giving Beacon access to all of SQL's Arizona-based Patient Service Centers and In-Office Phlebotomy locations. Beacon's clients and their patients will be able to have blood drawn, processed and shipped to Beacon's CLIA Laboratory for testing. This contract is in advance to Beacon's imminent market launch of its blood test for colorectal cancer screening, BeScreened-CRC.

September 2016

Beacon Biomedical Inc. is named an AZBio Fast Lane Honoree for 2016, will be honored during the 11th Annual

AZBio Awards Dinner on September 21st at the Phoenix Convention Center, and will be presenting at the AZBio White Hat Investors Conference on September 22nd.

July 2016

Beacon Biomedical Inc. Appoints Industry Veteran to Lead Cancer Screening Technology Commercialization.

Beacon Biomedical Inc. moves to new corporate offices and announces the opening of its new R&D and CLIA laboratory facilities.

June 2016

Beacon Biomedical Inc. to Present at Singular Research Spring Select "Best of the Uncovereds" Investment Conference on June 9, 2016

May 2016

Beacon Biomedical Inc. to Exhibit at BIO International Conference in San Francisco on June 6-9, 2016 

April 2016

Beacon Biomedical Inc. Appoints Industry Veteran To Lead Commercialization. Dave English had been appointed as Director of Business Development.

December 2015

Congratulations to Beacon Biomedical! They were named as 1 of the 6 winners in the Arizona Commerce Authority’s Fall 2015 round of the Arizona Innovation Challenge


Listen to Beacon Biomedical's CEO talk about their colon cancer screening test, ColoRT™ at ehealth radio https://t.co/mOMkMIMbDk

Beacon Biomedical, Inc., a privately held company focused on developing patient friendly cancer screening announced that it received an investment from Hyalescent Ventures.

October 2015

Beacon advances to the Semi-Finalist Round of the Arizona Commerce Authority's Fall 2015 Arizona Innovation Challenge as one of Top 25 Companies out of 131 applicants

September 2015

Beacon has been awarded a Phase I SBIR Grant for "Easy, Affordable & Accurate Point of Care Screening to Reduce Colorectal Cancer Disparities" from the National Institute of Biomedical Imaging and Biomedical Engineering at the National Institutes of Health.


  • 11:31
  • 10:38

Easy, Accurate and Affordable Cancer Screening....Welcome to the Beacon Revolution!


Welcome To Beacon Biomedical

Beacon Biomedical Inc. is a medical diagnostic device company on a mission...to save as many lives as possible by providing easy, accurate and affordable blood tests for earlier cancer detection.
Our laboratory developed test (LDT) solutions are being developed for primary care providers to be able to screen their patients for the presence of undiagnosed cancer. Our focus is on the screening non-compliant patient populations in order to improve earlier detection and survivability from these devastating diseases.

BeScreened™-CRC is Now Available To The Public!
Beacon is pleased to announce the release of our first blood-based screening test for the detection of  colorectal cancer (CRC).  It is called BeScreened™-CRC .  It's a CLIA approved laboratory developed test (LDT) that is 95% accurate at detecting stages I-IV CRC.  Additionally, in preliminary studies it has demonstrated greater than 60% sensitivity at detecting precancerous polys (advanced adenomas).  BeScreened™-CRC is now available through partnering Accountable Care Organizations (ACOs) and Independent Physician Offices. 

Practitioners interested in providing BeScreened-CRC to your screening non-compliant patients, please contact Beacon for more details. Since it is a new test on the market, we ask that patients contact the Company to check on its availability in your area.